Talis Biomedical Corporation - common stock (TLIS)
4.3800
0.00 (0.00%)
Talis Biomedical Corp is a biotechnology company focused on developing innovative diagnostic solutions for infectious diseases
The company aims to enhance the speed and accuracy of pathogen detection through its proprietary technology platform, which integrates molecular diagnostics with advanced automation. By creating devices that can deliver rapid test results, Talis seeks to improve patient care and facilitate timely decision-making in clinical environments, particularly in the context of critical conditions where early diagnosis is essential.
Talis Biomedical shares are trading lower by 49% to $4.58 during Wednesday's session. The company announced board restructuring, appointed new directors and updated investors on potential bankruptcy proceedings.
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Talis Biomedical Corporation Talis Biomedical Corporation (NASDAQ: TLIS), TaskUs, Inc. (NASDAQ: TASK), and Rent the Runway, Inc. (NASDAQ: RENT) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO. Our investigation concerns whether the board of directors of Talis have breached their fiduciary duties to the company.
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO. Our investigation concerns whether the board of directors of Talis have breached their fiduciary duties to the company.
Talis Biomedical Corp (NASDAQ: TLIS) shares are trading higher by 30% to $7.03 Tuesday morning after the company announced it is exploring strategic options to boost shareholder value due to
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter financial results.
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
